Editorial Material
Hematology
Heinz Zoller, Sonja Wagner, Benedikt Schaefer
Summary: This study found that hypophosphataemia is a common side-effect in patients with iron deficiency anaemia treated with ferric carboxymaltose, and it may even require intravenous supplementation of phosphate with unknown long-term consequences.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Medicine, General & Internal
Hye Won Shin, Doo Yeon Go, Suk Woo Lee, Yoon Ji Choi, Eun Ji Ko, Hae Sun You, Yoo Kyung Jang
Summary: This systematic review compared the efficacy and safety of ferric carboxymaltose (FCM) and iron sucrose (IS) in treating iron deficiency anemia (IDA) in obstetric and gynecologic patients. The results showed that FCM was more effective in increasing Hb and ferritin levels compared to IS, with a more favorable safety profile.
Article
Pediatrics
Patricia Garcia-Ortega, Ines Jimenez-Lozano, Alejandro Cruz, Aurora Fernandez Polo, Mercedes Lopez, Gema Ariceta
Summary: This study retrospectively evaluated the safety and effectiveness of FCM treatment in pediatric patients with CKD non-dependent of hemodialysis. The results showed that FCM can improve anemia and is well-tolerated in pediatric patients with CKD, with a low incidence of adverse effects.
FRONTIERS IN PEDIATRICS
(2022)
Article
Multidisciplinary Sciences
Saki Tahara, Yoshiro Naito, Keisuke Okuno, Seiki Yasumura, Tetsuo Horimatsu, Junichi Ohno, Isamu Sunayama, Yuki Matsumoto, Eri Manabe, Kumiko Masai, Kohei Azuma, Koichi Nishimura, Kyung-Duk Min, Akiko Goda, Masanori Asakura, Masaharu Ishihara
Summary: Anemia and iron deficiency are common in patients with heart failure, and IV administration of iron improves outcomes in patients with decompensated heart failure and iron deficiency. The current diagnostic methods for iron deficiency have limitations, and alternative methods should be considered. Reticulocyte hemoglobin equivalent (Ret-He) is a potential indicator for iron content, but its clinical utility in patients with heart failure remains uncertain. Further investigation is needed to determine the clinical usefulness of Ret-He in identifying iron deficiency, predicting response to IV iron, and prognosis in patients with heart failure.
SCIENTIFIC REPORTS
(2022)
Review
Medicine, Research & Experimental
John A. Glaspy, Myles Wolf, William E. Strauss
Summary: Some intravenous iron formulations can lead to severe hypophosphatemia, especially in patients treated with ferric carboxymaltose. The consequences of severe HPP are usually bone abnormalities. However, there are still uncertainties and limitations in the research on HPP.
ADVANCES IN THERAPY
(2021)
Article
Oncology
Jie Jin, Zhihua Ran, Emanuele Noseda, Bernard Roubert, Matthieu Marty, Anna Mezzacasa, Udo Michael Goring
Summary: Ferric carboxymaltose (FCM) and iron sucrose (IS) have similar effects in treating iron deficiency anemia (IDA), but FCM shows a faster hemoglobin response and correction of iron deficiency.
FRONTIERS OF MEDICINE
(2023)
Article
Medicine, General & Internal
Roberto Minutolo, Patrizia Berto, Maria Elena Liberti, Nicola Peruzzu, Silvio Borrelli, Antonella Netti, Carlo Garofalo, Giuseppe Conte, Luca De Nicola, Lucia Del Vecchio, Francesco Locatelli
Summary: In non-hemodialysis CKD patients, ferric carboxymaltose (FCM) effectively corrects iron-deficient anemia and allows remarkable cost savings from societal, healthcare, and patient perspectives.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Alberto Rosati, Paolo Conti, Patrizia Berto, Sabrina Molinaro, Federica Baldini, Colin Gerard Egan, Vincenzo Panichi
Summary: This study confirms the efficacy, safety, and cost-effectiveness of intravenous ferric carboxymaltose (FCM) in correcting iron deficiency anemia (IDA) in hemodialysis patients. FCM treatment significantly improved hemoglobin levels, increased transferrin saturation and ferritin parameters, and reduced the use of erythropoiesis-stimulating agents.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Hyo-Hyun Kim, Eun Hye Park, Seung Hyun Lee, Kyung-Jong Yoo, Young-Nam Youn
Summary: Patients with iron deficiency anemia (IDA) who were scheduled for off-pump coronary artery bypass grafting (OPCAB) were randomly assigned to receive either intravenous ferric carboxymaltose (IVFC) or placebo treatment. The IVFC treatment significantly reduced the need for red blood cell and platelet transfusions, and patients in the IVFC group had higher levels of hematologic parameters and iron concentrations after surgery. Preoperative IVFC treatment improved the values of hematologic parameters and iron bioavailability in patients with IDA undergoing OPCAB.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
S. Secilmis, D. Iskender, B. A. Candir, E. Bozan, S. Yaman, B. U. Ulu, T. N. Yigenoglu, M. K. Cakar, M. S. Dal, F. Altuntas
Summary: This study demonstrates that ICM is an effective and safe treatment option for patients with IDA due to HMB. All anemia parameters showed significant improvement four weeks after treatment, with minimal side effects.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2022)
Review
Pediatrics
Ayseguel Aksan, Fred Zepp, Sangeetha Anand, Juergen Stein
Summary: This narrative review examines the efficacy and safety of intravenous ferric carboxymaltose (FCM) in treating iron deficiency or iron deficiency anaemia in children and adolescents. Although the majority of publications are retrospective studies or case reports, they suggest that FCM is an effective and generally well-tolerated treatment for this condition. However, prospective, randomised controlled trials are still needed to further confirm its efficacy and safety.
EUROPEAN JOURNAL OF PEDIATRICS
(2022)
Article
Anesthesiology
Filippo Corsi, Annalisa Pasquini, Manuel Guerrera, Francesca Bevilacqua, Temistocle Taccheri, Maria Enrica Antoniucci, Maria Calabrese, Caterina Giovanna Valentini, Nicoletta Orlando, Martina Bartolo, Giorgio Cannetti, Claudio Pellegrino, Franco Cavaliere, Luciana Teofili
Summary: This study investigated the prevalence of iron deficiency (ID) among cardiac surgery patients and examined whether screening and treating ID patients before surgery could reduce transfusion requirements. The results showed that short-term pre-operative iron therapy can reduce postoperative transfusions and lower hospitalization costs.
JOURNAL OF CLINICAL ANESTHESIA
(2023)
Article
Gastroenterology & Hepatology
Trond Espen Detlie, Jonas Christoffer Lindstrom, Marte Eide Jahnsen, Elisabeth Finnes, Heinz Zoller, Bjorn Moum, Jorgen Jahnsen
Summary: High-dose intravenous iron is an effective treatment option for iron deficiency in IBD, but treatment with FCM has been associated with the development of hypophosphatemia. This study found that FCM-treated patients had significantly higher fibroblast growth factor 23 levels and decreased vitamin D and calcium levels compared to patients who received FDI, but no significant short-term clinical impact of hypophosphatemia was demonstrated.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Nutrition & Dietetics
Ludovica Dottori, Daniil Corleone Tsar'kov, Emanuele Dilaghi, Giulia Pivetta, Silvia Scalamonti, Irene Ligato, Gianluca Esposito, Bruno Annibale, Edith Lahner
Summary: This retrospective study evaluated the safety and efficacy of ferric carboxymaltose (FCM) in treating Corpus Atrophic Gastritis (CAG)-related iron deficiency anaemia (IDA). The results showed that FCM was both safe and effective in improving haemoglobin and iron storage in patients, leading to quick and long-lasting recovery. However, there is a risk of IDA relapse.
Article
Medicine, General & Internal
Hea Ree Park, Su Jung Choi, Eun Yeon Joo
Summary: This study retrospectively evaluated the effectiveness of repeated intravenous ferric carboxymaltose (FCM) treatment for restless legs syndrome (RLS) patients. The results showed that repeated IV FCM was an effective treatment for primary RLS and RLS associated with iron deficiency. Serum ferritin might not be a reliable factor to monitor the sustained effects of IV iron for RLS.
JOURNAL OF CLINICAL MEDICINE
(2022)